Winser A, Ledermann JA, Osborne R, Gabra H, El-Bahrawy MA. Survey of the management of borderline ovarian tumors in the United Kingdom. World J Obstet Gynecol 2012; 1(2): 3-13 [DOI: 10.5317/wjog.v1.i2.3]
Corresponding Author of This Article
Dr. Mona A El-Bahrawy, MBBCh, PhD, FRCPath, Department of Histopathology, Imperial College London, Hammersmith Hospital, DuCane Road, London W12 0NN, United Kingdom. m.elbahrawy@imperial.ac.uk
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Obstet Gynecol. Aug 10, 2012; 1(2): 3-13 Published online Aug 10, 2012. doi: 10.5317/wjog.v1.i2.3
Survey of the management of borderline ovarian tumors in the United Kingdom
Amy Winser, Jonathan A Ledermann, Richard Osborne, Hani Gabra, Mona A El-Bahrawy
Amy Winser, Clinical Trials Unit, The Royal Marsden Hospital, London SW3 6JJ, United Kingdom
Jonathan A Ledermann, UCL Hospitals Biomedical Research Centre, UCL Cancer Institute, London WC1E 6BT, United Kingdom
Richard Osborne, Dorset Cancer Centre, Poole Hospital, Dorset BH15 2JB, United Kingdom
Hani Gabra, Department of Oncology, Imperial College London, Hammersmith Hosptial, London W12 0NN, United Kingdom
Mona A El-Bahrawy, Department of Histopathology, Imperial College London, Hammersmith Hosptial, London W12 0NN, United Kingdom
Author contributions: Winser A arranged the electronic development and distribution of the survey; Ledermann JA, Osborne R and Gabra H planned the survey questions; Osborne R revised the manuscript; El-Bahrawy MA designed and developed the survey, analyzed the responses and wrote the manuscript.
Supported by The NIHR Biomedical Research Centre
Correspondence to: Dr. Mona A El-Bahrawy, MBBCh, PhD, FRCPath, Department of Histopathology, Imperial College London, Hammersmith Hospital, DuCane Road, London W12 0NN, United Kingdom. m.elbahrawy@imperial.ac.uk
Telephone: +44-20-83833442 Fax: +44-20-83838141
Received: May 9, 2012 Revised: June 24, 2012 Accepted: July 30, 2012 Published online: August 10, 2012
Abstract
Borderline ovarian tumors (BOTs) represent approximately 10% of ovarian neoplasms and are a heterogeneous group of tumors with variable biological behaviour. The majority present with disease confined to the ovary and have an excellent prognosis after surgical removal. A small proportion subsequently has recurrent disease or progression to invasive cancer. Tumor recurrence can occur up to 20 years after surgical resection. There are no robust clinical, histological or molecular markers that distinguish high risk cases and no satisfactory treatment for patients with progressive disease. This results in great variability in management in different centres. We conducted a national survey on the management of borderline ovarian tumors in cancer centres representing different regions in the United Kingdom. In this article we review the literature for the current concepts in diagnosis, treatment and follow up of BOTs and we report the results of the survey of current practice in the United Kingdom. On that basis we provide recommendations for the management of patients with BOTs.
